Department of Psychiatry, UCSD School of Medicine, 9500 Gilman Dr., La Jolla, CA 92093-0804, United States.
Department of Psychiatry, UCSD School of Medicine, 9500 Gilman Dr., La Jolla, CA 92093-0804, United States.
Schizophr Res. 2018 Sep;199:285-291. doi: 10.1016/j.schres.2018.03.037. Epub 2018 Apr 5.
Many patients with chronic psychotic disorders including schizophrenia (SZ) maintain meaningful levels of plasticity (i.e., capacity for change) within neurocognition-relevant brain mechanisms, as evidenced by gains in neurocognition and function after interventions such as targeted cognitive training. However, like many clinical features of these disorders, therapeutic responses in SZ are heterogeneous, and prospectively identifying treatment-sensitive individuals and individualized treatment modalities remains an unmet challenge. We propose that available plasticity in neurocognition-relevant brain mechanisms in individual SZ patients can be detected by gains in laboratory measures of early auditory information processing (EAIP) and auditory learning after a single challenge-dose of a pharmacologic agent; here, we present supportive data for this strategy with the non-competitive NMDA antagonist, memantine, and the psychostimulant, amphetamine. We describe a novel therapeutic model where this "challenge dose" strategy is used to prospectively identify a sensitive cohort of patients, and in these patients, a therapeutic response is elicited by pairing drug-enhanced EAIP and auditory learning with auditory-based targeted cognitive training.
许多患有慢性精神病障碍(包括精神分裂症)的患者在神经认知相关的大脑机制中保持着有意义的可塑性水平(即改变的能力),这可以通过靶向认知训练等干预措施后神经认知和功能的提高来证明。然而,与这些疾病的许多临床特征一样,精神分裂症的治疗反应是异质的,前瞻性地识别治疗敏感个体和个体化治疗方式仍然是一个未满足的挑战。我们提出,通过单次药物挑战剂量后实验室测量的早期听觉信息处理(EAIP)和听觉学习的增益,可以检测个体精神分裂症患者神经认知相关大脑机制中的可用可塑性;在这里,我们用非竞争性 NMDA 拮抗剂美金刚和苯丙胺来支持这一策略的数据。我们描述了一种新的治疗模型,其中使用这种“挑战剂量”策略来前瞻性地识别敏感患者群体,并且在这些患者中,通过将药物增强的 EAIP 和听觉学习与基于听觉的靶向认知训练相结合,来引起治疗反应。